カテゴリ
お知らせ トランス LGB(TIQ) HIV/AIDS 米政治 国内政治 ジェンダー・セックス バックラッシュ Books Movies Theatres TV & Radio Music Others Opinions 以前の記事
2007年 09月 2007年 08月 2007年 07月 2007年 06月 2007年 05月 2007年 04月 2007年 03月 2007年 02月 2007年 01月 2006年 12月 2006年 11月 2006年 10月 2006年 09月 2006年 08月 2006年 07月 2006年 06月 2006年 05月 2006年 04月 2006年 03月 2006年 02月 2006年 01月 2005年 12月 2005年 11月 2005年 10月 2005年 09月 2005年 08月 2005年 07月 検索
最新のトラックバック
その他のジャンル
ファン
記事ランキング
ブログジャンル
画像一覧
|
FDA、緊急経口避妊薬の店頭販売の最終判断を60日間延期 (日本経済 2005/08/29)
ワシントン(ウォール・ストリート・ジャーナル)米食品医薬品局(FDA)は26日、米製薬会社バー・ファーマシューティカルズ(NYSE:BRL)の緊急経口避妊薬「プランB」について、処方せんなしの店頭販売を認めるかどうかの最終的判断を延期するとバーに通知した。思春期の少女に対して同薬をどう販売するかの懸念を理由としている。 FDAは17歳以上の女性を対象とする、"モーニングアフターピル"と呼ばれるプランBの店頭販売承認に対する最終決定を60日間延期する。 注目を集めてきた決定がまた先送りされることになる。FDAの諮問委員会は2003年12月、プランBの店頭販売を認めるよう勧告することを賛成23、反対4の賛成多数で決めた。しかしFDAは2004年5月、思春期の少女によるプランBの使用をめぐる懸念から、その勧告には従わず、店頭販売は認めない決定をバーに通知した。 バーはこうした懸念に対処するため、2度目の承認申請をFDAに提出した。 FDAは7月、プランBについての決定を9月1日までに行う方針を示していた。 プランBは通常の避妊薬の高用量ピルで、避妊手段を取らなかった性交後72時間以内に服用すれば89%の確率で妊娠を防ぐことができる。 科学者によると、プランBは服用後、ホルモン、プロゲスチンを急増させ排卵に干渉する、あるいは排卵がすでに起きている場合は胚が子宮に着床するのを防ぐ。プランBは12時間の間隔をあけて2回服用しなければならない。すでに妊娠している女性に効き目はない。また問題の「RU-486」ピルとは異なり、中絶を誘発するものでもない。 バーの26日付のプレスリリースによると、プランBについて一般からコメントを求めたいとして最終判断を延期すると伝える書簡をFDAから受け取った。 バー株の26日終値は前日比1.09ドル(2.35%)安の45.22ドル。 プランBの店頭販売反対派は、これを認めれば、若者の性が乱れ、性感染症発生率が上昇すると主張。 賛成派は意図しなかった妊娠を予防することにつながり、中絶の必要性を減らすと指摘。しかし真の違いを生むには、女性が迅速にプランBを手に入れられる必要があるとしている。 The New York Times August 28, 2005 Morning-After Pill: Politics and the F.D.A. By GARDINER HARRIS WASHINGTON, Aug. 27 - For more than a year, federal drug officials have insisted that their repeated delays in deciding whether to approve over-the-counter sales of a morning-after contraceptive have nothing to do with abortion politics. Among veterans of the battles over drug approvals here, it is hard to find anyone who believes them. On Friday, the food and drug commissioner, Lester M. Crawford, announced that he would indefinitely postpone a ruling on Plan B, the morning-after pill made by Barr Laboratories. He explained that while the science supported over-the-counter access for women 17 and older, the agency had not figured out how to do that without younger teenagers getting the pills. While the announcement prompted familiar responses on each side of the abortion debate - protest from abortion rights groups, support from abortion opponents - other veterans of the drug wars sounded more exasperated than anything else. "At some point, the statute requires that the agency make a decision," said Dr. Eve E. Slater, an assistant secretary of health from 2001 to 2003. "You can't just delay forever." The Plan B decision has become "overly politicized, and it shouldn't be," Dr. Slater added. Under federal regulations, the Food and Drug Administration was required to reach a decision on Plan B by January. Nothing happened. Indeed, Barr executives said they had no discussions with the agency after January. Usually when the agency is actively considering an application, there is a constant back-and-forth with the company. As the months passed, two Democratic senators who support abortion rights, Hillary Rodham Clinton of New York and Patty Murray of Washington, vowed to block any vote on President Bush's nomination of Dr. Crawford to become agency commissioner unless the F.D.A. made a decision on the pill, for or against. Mr. Bush has long been aligned with abortion opponents. The senators relented in July after the secretary of health and human services, Michael O. Leavitt, promised that a decision would be made by Sept. 1. On Friday, both senators attributed Dr. Crawford's latest announcement to political interference. Dr. Robert Fenichel, a former deputy division director for cardiovascular and renal drugs who left the F.D.A. in 2000, agreed, saying the agency's decisions on Plan B were being driven by abortion politics. "I've never seen anything like this before," Dr. Fenichel said. That the Plan B fight is politically charged is nothing new, of course. During Dr. Crawford's confirmation hearings, Senator Orrin G. Hatch, Republican of Utah and a supporter of Dr. Crawford, called it not "a pharmaceutical issue as much as it's a social issue." Nor is it new that politics would play an important role in the decisions of the F.D.A. or any other politically appointed regulatory agency. Elliott Millenson, former president and chief executive of Direct Access Diagnostics, a company that sought to sell an at-home test for H.I.V. infection in the 1980's and 90's, recalled that when gay rights groups opposed the test, the agency initially refused even to accept the company's application. "The commissioner's office explicitly told us in 1992 that if we wanted approval we would need to get political support for our product," Mr. Millenson said. He sued the agency and won. The agency eventually approved the test, although for business reasons the company never sold any. "On sensitive issues, politics are business as usual at the F.D.A.," Mr. Millenson said. The agency approved Plan B as a prescription contraceptive in July 1999. The pill provides a concentrated dose of the medicines available in most daily birth control pills; it can prevent pregnancy if taken as long as 72 hours after intercourse. Many abortion opponents view it as tantamount to abortion. The F.D.A.'s announcement on Friday led to open bickering between abortion rights advocates and Barr executives. Publicly, the two sides have been supportive of each other for nearly two years, but privately, they have long disagreed on strategy. In May 2004, the food and drug agency rejected Barr's application to sell its drug over the counter, saying the company had failed to provide enough information about how well girls younger than 16 understood the drug's label and whether they might engage in riskier sex if the drug was easily available. At that point, Barr had two choices. It could have undertaken another "label-comprehension" study with scores of young teenagers and then resubmitted an almost identical application. Or it could have used the data that it had on hand and reapplied to sell the drug as an over-the-counter pill only to women 16 years of age and older. Younger girls would have to get a prescription. On Friday, the agency changed the age to 17. Kirsten Moore, president of the Reproductive Health Technologies Project, an abortion rights advocacy group here, said she and fellow advocates suggested that Barr do another label study. Barr decided to reapply with existing data. No one knows whether the advocates' strategy would have worked, but Barr's has not, at least so far. Ms. Moore said label-comprehension studies were relatively easy, cheap and quick to perform. Most are done in malls, where researchers set up a table and ask passers-by to read a drug label and answer a few questions. Bruce Downey, Barr's chairman and chief executive, said he did not regret the company's actions. And Dr. Carol Ben-Maimon, chief of Barr's proprietary research, said F.D.A. officials never told the company exactly what questions a new study should answer. In addition to label comprehension, the agency voiced concerns about Plan B's effects on sexual promiscuity and sexually transmitted diseases, Dr. Ben-Maimon said. To answer those questions, a quick study at a mall would not suffice, she said. Dr. Crawford said Friday that the F.D.A. would seek public comments over the next 60 days on whether it had the authority to approve Barr's application and whether it could enforce any regulation that would stop girls younger than 17 from buying the pill freely. Ms. Moore said she and other abortion-rights advocates wanted Barr to withdraw its present application, perform a label-comprehension study and then apply to sell the drug over-the-counter to women of all ages. Rejecting the application again if it contained clear data showing that young teenagers understood how to use the drug would be more difficult for the agency to justify with scientific or regulatory rationales, she said. "It's time to call F.D.A.'s bluff," Ms. Moore added. Mr. Downey, of Barr, said the company was considering a new label-comprehension trial and added that it would provide comments to the F.D.A. during the next 60 days. Whether the agency will listen to those comments is unclear. "We volunteered repeatedly to put proposals forth to the F.D.A.," Dr. Ben-Maimon said. "They didn't really seek out our opinions or thoughts on how we could implement them." Yahoo! News Full Coverage - Birth Control
by alfayoko2005
| 2005-08-29 14:08
| ジェンダー・セックス
|
ファン申請 |
||